Giant cell tumour of bone is a locally aggressive osteolytic neoplasm that typically arises in the long bones. However, discovering a cervical giant cell tumour poses an exceptional diagnostic challenge for spine specialists. Because mobile spine involvement remains rare, clinicians frequently misdiagnose this lesion initially. Prompt cytomorphologic identification prevents progressive neurological deficits and guides spinal reconstruction.

Clinical Presentation and Anatomy of Cervical Lesions

Vertebral neoplasms in the cervical spine produce distinct clinical signs due to the compact regional anatomy. Patients typically report persistent neck pain, restricted cervical range of motion, and localized tenderness. In addition, compression of adjacent nerve roots or the spinal cord frequently triggers neurological symptoms. For instance, patients may experience progressive upper-limb paresthesias, radiating numbness, and motor weakness. In this cervical case, an expansile osteolytic lesion involved multiple vertebral levels from C2 to C4. Consequently, the patient developed posterior neck swelling and radiating neurological discomfort. Because cervical spondylosis and degenerative disk disease occur far more commonly in older adults, clinicians often mistake these initial signs for mechanical disorders. Furthermore, spinal involvement accounts for less than five percent of all primary giant cell neoplasms. Therefore, physicians must maintain high vigilance whenever a patient presents with unremitting cervical pain. Timely diagnostic intervention preserves critical neurological function.

Radiologic Features of Cervical Giant Cell Tumour

Diagnostic imaging plays a pivotal role in delineating osseous destruction within the cervical spine. Computed tomography scans typically reveal an expansile, geographic osteolytic lesion lacking peripheral sclerotic rims. Furthermore, cross-sectional imaging clearly demonstrates cortical thinning, cortical disruption, and pathological vertebral collapse. In advanced spinal cases, the tumor regularly breaches the cortex to form an epidural soft tissue mass. Magnetic resonance imaging subsequently clarifies the degree of thecal sac compression and nerve root involvement. On magnetic resonance sequences, the neoplasm characteristically shows low-to-intermediate signal intensity on T1-weighted images and heterogeneous intensity on T2-weighted scans. Moreover, prominent hemosiderin deposits cause low signal on gradient-echo acquisitions. Contrast-enhanced studies reveal vivid, heterogeneous enhancement within solid components. Additionally, secondary aneurysmal bone cysts can produce prominent fluid-fluid levels. Consequently, radiologists must differentiate this destructive process from spinal tuberculosis, chordoma, and osteolytic metastases. Correlating radiological and clinical findings directs percutaneous biopsy.

Cytomorphology and Fine-Needle Aspiration Hallmarks

Computed tomography-guided fine-needle aspiration cytology provides a rapid, minimally invasive method for diagnosing spinal lesions. Pathologists evaluate highly cellular aspirate smears displaying a dual cell population under microscopic examination. Specifically, the smears contain cohesive clusters and dispersed syncytial sheets of bland mononuclear stromal cells. In addition, numerous multinucleated osteoclast-type giant cells lie uniformly distributed among these stromal cells. Notably, the nuclei of both the giant cells and the mononuclear stromal cells exhibit identical cytological characteristics. Both cell types share round-to-oval vesicular nuclei with delicate chromatin and small nucleoli. This striking nuclear synchrony serves as an indispensable hallmark for accurate diagnosis. Furthermore, pathologists observe an absence of significant nuclear atypia, atypical mitotic figures, or coagulative tumor necrosis. Malignant osteoid production is also entirely absent. Therefore, recognizing this classic cytomorphological pattern enables an accurate preoperative diagnosis on fine-needle aspirates. This cytologic certainty avoids unnecessary exploratory surgery.

Differential Diagnosis of Giant Cell-Rich Lesions

Distinguishing giant cell-rich vertebral lesions requires meticulous cytological and histological evaluation. For instance, aneurysmal bone cysts represent a frequent diagnostic mimic, exhibiting bloody aspirates and reactive giant cells. However, aneurysmal bone cysts lack the sheets of uniform mononuclear stromal cells characteristic of true giant cell neoplasms. Similarly, brown tumours of hyperparathyroidism show clusters of osteoclasts around areas of heavy hemosiderin deposition. Consequently, clinicians must test serum calcium, phosphate, and parathyroid hormone levels to exclude hyperparathyroidism. In addition, osteoblastomas feature reactive osteoclasts alongside prominent osteoblastic seams and osteoid trabeculae. Giant cell-rich osteosarcoma represents another critical differential entity. In contrast to benign lesions, osteosarcoma demonstrates severe cytological anaplasia, hyperchromatic bizarre nuclei, atypical mitoses, and direct malignant osteoid. Furthermore, tenosynovial giant cell tumors contain histiocytoid cells with distinctive foamy cytoplasm. Therefore, recognizing uniform stromal nuclei and correlating clinicoradiologic data prevents misclassifying benign lesions as high-grade sarcomas.

Multidisciplinary Management and Prognostic Outcomes

Treating cervical vertebral lesions requires close collaboration among spine surgeons, oncologists, and pathologists. Complete surgical resection represents the traditional goal to minimize recurrence. However, performing wide en bloc resection in the cervical spine presents formidable anatomical challenges. Proximity to the vertebral arteries and spinal cord frequently limits clear margins. Consequently, surgeons often utilize intralesional curettage combined with high-speed burring and reconstructive cervical stabilization. In addition, medical therapy has revolutionized management protocols for challenging lesions. Specifically, denosumab, a monoclonal antibody targeting receptor activator of nuclear factor kappa-B ligand, halts osteoclast-mediated bone destruction. Preoperative denosumab therapy induces lesion consolidation, reconstitutes cortical margins, and reduces intraoperative bleeding. Furthermore, long-term postoperative surveillance with magnetic resonance imaging remains essential, as local recurrence rates approach twenty percent. Clinicians also monitor chest imaging periodically to identify rare benign pulmonary implants. Therefore, combined surgical and medical approaches deliver optimal long-term disease control.

Frequently Asked Questions

What causes giant cell tumour of bone in the cervical spine?

The exact trigger remains unknown, but neoplastic mononuclear stromal cells drive giant cell tumour development. These mononuclear stromal cells express receptor activator of nuclear factor kappa-B ligand at elevated levels. Consequently, this ligand overproduction recruits non-neoplastic circulating monocytes and fuses them into numerous osteoclast-like multinucleated giant cells. These osteoclastic giant cells subsequently cause extensive osteolysis, cortical erosion, and vertebral bone destruction in the cervical spine.

How does fine-needle aspiration cytology differentiate giant cell tumours from osteosarcoma?

Fine-needle aspiration cytology distinguishes these lesions by evaluating nuclear atypia and matrix components. Giant cell tumours demonstrate bland, uniform mononuclear stromal cells with identical nuclei to osteoclast-type giant cells, without pleomorphism or atypical mitoses. In contrast, osteosarcomas exhibit prominent cellular anaplasia, marked hyperchromasia, abnormal mitotic figures, and direct malignant osteoid formation. Consequently, cytopathologists identify these distinctive malignant features to prevent misdiagnosing high-grade sarcomas as benign giant cell lesions.

What role does denosumab play in treating spinal giant cell tumours?

Denosumab functions as a targeted monoclonal antibody that binds receptor activator of nuclear factor kappa-B ligand. By halting osteoclast recruitment and activation, denosumab dramatically arrests tumor-induced bone destruction. Furthermore, this pharmacological inhibition promotes new cortical bone mineralization and diminishes hypervascularity within vertebral lesions. Surgeons frequently administer denosumab preoperatively to consolidate extensive cervical tumors, thereby facilitating safer operative curettage, reducing intraoperative blood loss, and optimizing spinal reconstruction outcomes.

Disclaimer: This content is for informational and educational purposes only and should not be taken as professional medical advice. Always consult a qualified healthcare provider for diagnosis and treatment of medical conditions. The views expressed are those of the authors and do not necessarily reflect the official policy or position of any medical institution. Refer to the latest local and national guidelines for clinical practice.

References

Duggal N et al. A Giant in the Neck: Cytomorphology of a Rare Cervical Vertebral Lesion. Cytopathology. 2026 Sep 26. doi: 10.1111/cyt.70135. PMID: 42798294.

van der Heijden L, Dijkstra PDS, Campanacci DA, Gibbons CLMH. Giant cell tumor of bone in the mobile spine: a multidisciplinary challenge. Lancet Oncol. 2014;15(11):e514-e523.

Chakarun CJ, Forrester DM, Gottsegen CJ, Patel DB, White EA, Matcuk GR Jr. Giant cell tumor of bone: review, mimics, and new concepts in imaging and histology. Skeletal Radiol. 2013;42(7):929-942.